In accordance with the timetable agreed by the Committee for Proprietary Medicinal Products at its meeting of 26-27 April 1995, the draft assessment report was circulated on 22 May 1995 by the Rapporteur to other Members of the Committee for Proprietary Medicinal Products and the companies involved.